Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Heron Therapeutics Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is far larger — about 72.5× Heron Therapeutics Inc's market cap, and VanEck JP Morgan EM Local Currency Bond ETF is more actively traded (2,843,860 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Heron Therapeutics Inc for 35 Days on average.
| EMLC | HRTX | |
|---|---|---|
Market Cap | $4.93B | $68.01M |
Volume | 2,843,860 | 1,891,941 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $1.49 |
52-Week Low | $24.53 | $0.27 |
Typical Hold Time | 38 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.77, down 0.24% on the day and hitting a new 52-week low. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though emerging market bonds have shown relative outperformance in 2026. Recent dividends of $0.14 and $0.13 were declared for October and August 2026 respectively.
The outlook remains cautious as dollar strength and rising global bond yields create challenges for emerging market local currency debt. While diversification benefits exist, near-term performance depends on currency dynamics and Federal Reserve policy direction. Key risks include currency volatility and global interest rate movements affecting bond valuations.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
